OncoMatch/Clinical Trials/NCT04222062
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
Is NCT04222062 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carmustine 7.7Mg Wafer for brain tumor - metastatic.
Treatment: Carmustine 7.7Mg Wafer — This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: surgery or radiation to area of planned resection
Prior treatment to the area of planned resection (surgery, radiation)
Cannot have received: whole brain radiation therapy
Prior whole brain radiation therapy
Lab requirements
Blood counts
Laboratory values adequate for patient to undergo surgery safely as determined by the attending neurosurgeon (transfusion permitted to reach goals); Normal coagulation studies (international normalized ratio, INR, ≤ 1.3)
Cardiac function
No New York Heart Association > Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication; No uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes)
Laboratory values adequate for patient to undergo surgery safely as determined by the attending neurosurgeon (transfusion permitted to reach goals); Normal coagulation studies (international normalized ratio, INR, ≤ 1.3); Severe pulmonary, cardiac or other systemic disease, specifically: New York Heart Association > Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication; Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea, according to Common Terminology Criteria for Adverse Events 5.0)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Henry Ford · Detroit, Michigan
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify